IMRN - Immuron Ltd ADR logo

Immuron Ltd ADR

IMRN
Rev 51xtop 1%Revenue grew 100% of years5Y
Compare IMRN Hold

Immuron Ltd is a biopharmaceutical company that develops and commercializes polyclonal antibodies. It offers Travelan, an OTC medicine to prevent travelers' diarrhea, and Protectyn, an immune supplement, along with several therapeutics in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ AUD
$1,000 invested 5 years ago โ†’$269today

Score Overview

1 Year
Score
Net Growth28.01%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth3.54%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.8
Net Growth55.22%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth51x
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Score
Net Growth44.82%
Net Trend56%
Net Income Consistency
Rev Growth440.40%
Rev Trend89%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Immuron Ltd ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IMRN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.95โ€”
1 Year2025-10-23
$ 2.16-55.86%
5 Years2021-10-22
$ 3.55-73.14%
All Time2017-06-09
$ 8.36-88.59%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in AUD

Year
2026$ 7M-$ 3M$ 9M
2025$ 7M-$ 5M$ 5M
2024$ 4M-$ 6M$ 11M
2023$ 1M-$ 3M$ 18M
2022$ 765.19K-$ 2M$ 22M
2021$ 145.78K-$ 8M$ 25M
2020$ 2M-$ 2M$ 3M
2019$ 2M-$ 4M$ 5M
2018$ 1M-$ 3M$ 4M
IPO2017$ 1M-$ 6M$ 3M
IMRN - Immuron Ltd ADR logo

Immuron Ltd ADR fundamental performance

Between 2021 and 2026, revenue grew from $ 145.78K to $ 7M and net income went from -$ 8M to -$ 3M. Revenue increased in every one of those 5 years; net income in 3.

Across Immuron Ltd ADR's full reported history, from 2017 to 2026, revenue grew from $ 1M to $ 7M and net income went from -$ 6M to -$ 3M. Revenue increased in 89% of the years measured; net income in 56%.

Immuron Ltd ADR currently holds a 5-year HDB Score of 6.8 out of 10. How the HDB Score is calculated.

Membership

Explore IMRN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies